Petros Pharmaceuticals, Inc. SEC filings PTPI
Petros Pharmaceuticals, Inc. has 257 filings in SEC EDGAR's recent list, going back to Jul 24, 2020. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 30, 2026 (bankruptcy, officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 10-K | Filing | Mar 31, 2026 | Dec 31, 2025 |
| 25-NSE | Delisting notice | Nov 20, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 17, 2025 | — |
| CORRESP | Letter to the SEC | Mar 14, 2025 | — |
| PRER14A | Filing | Mar 14, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 13, 2025 | — |
| EFFECT | Filing | Feb 14, 2025 | — |
| CORRESP | Letter to the SEC | Feb 14, 2025 | — |
| CORRESP | Letter to the SEC | Feb 14, 2025 | — |
| CORRESP | Letter to the SEC | Feb 14, 2025 | — |
| CORRESP | Letter to the SEC | Feb 14, 2025 | — |
| CORRESP | Letter to the SEC | Feb 13, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 12, 2025 | — |
| CORRESP | Letter to the SEC | Feb 11, 2025 | — |
| CORRESP | Letter to the SEC | Feb 11, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2025 | — |
| EFFECT | Filing | May 20, 2024 | — |
| CORRESP | Letter to the SEC | May 17, 2024 | — |
| UPLOAD | Letter from the SEC | May 9, 2024 | — |
| NT 10-Q | Filing | Nov 15, 2023 | Sep 30, 2023 |
| EFFECT | Filing | Sep 18, 2023 | — |
| CORRESP | Letter to the SEC | Sep 15, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 16, 2023 | — |
| D | Filing | Jul 21, 2023 | — |
| EFFECT | Filing | Oct 20, 2022 | — |
| EFFECT | Filing | Jan 14, 2022 | — |
| CORRESP | Letter to the SEC | Jan 12, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 12, 2022 | — |
| CORRESP | Letter to the SEC | Jan 12, 2022 | — |
| D | Filing | Jan 3, 2022 | — |
| EFFECT | Filing | Dec 17, 2021 | — |
| CORRESP | Letter to the SEC | Dec 15, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 15, 2021 | — |
| D | Filing | Dec 3, 2021 | — |
| EFFECT | Filing | Nov 23, 2021 | — |
| CORRESP | Letter to the SEC | Nov 23, 2021 | — |
| CORRESP | Letter to the SEC | Nov 22, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 19, 2021 | — |
| D | Filing | Oct 26, 2021 | — |
| EFFECT | Filing | Feb 4, 2021 | — |
| CORRESP | Letter to the SEC | Feb 3, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 3, 2021 | — |
| 8-A12B | Filing | Dec 1, 2020 | — |
| SEC STAFF LETTER | Filing | Nov 3, 2020 | — |
| EFFECT | Filing | Oct 29, 2020 | — |
| CORRESP | Letter to the SEC | Oct 27, 2020 | — |
| SEC STAFF LETTER | Filing | Oct 22, 2020 | — |
| CORRESP | Letter to the SEC | Oct 15, 2020 | — |
| CORRESP | Letter to the SEC | Sep 30, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 20, 2020 | — |
Showing 50 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PTPI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1815903
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.